The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.
Aditya Bardia
No relevant relationships to disclose
Dejan Juric
No relevant relationships to disclose
Steven J. Isakoff
No relevant relationships to disclose
Darrell R. Borger
Consultant or Advisory Role - Bio-Reference Laboratories
Dora Dias-Santagata
Consultant or Advisory Role - Bio-Reference Laboratories
Michaela Jane Higgins
No relevant relationships to disclose
Anthony John Iafrate
Consultant or Advisory Role - Bio-Reference Laboratories
Keith Flaherty
No relevant relationships to disclose
Beverly Moy
No relevant relationships to disclose
Leif William Ellisen
Consultant or Advisory Role - Bio-Reference Laboratories